[Dizhe Pharmaceutical: Net profit in the first three quarters was 3.639 billion yuan, turning losses into profits year-on-year] On October 30, Dizhe Medicine (688192.SH) announced that it achieved operating income of 4.77 billion yuan in the first three quarters, a year-on-year increase of 713.5%; net profit attributable to shareholders of listed companies was 3.639 billion yuan, turning losses into profits year-on-year. In the third quarter, operating income was 4.247 billion yuan, a year-on-year increase of 1736.09%; net profit attributable to shareholders of listed companies was 3.849 billion yuan, turning losses into profits year-on-year. The change in performance was mainly due to the conclusion of a global licensing cooperation with Schweizer®, the receipt of a down payment of US$600 million and the satisfaction of revenue recognition conditions, and the one-time recognition of licensing revenue. Xiaocai's note: The company's Q3 net profit was 3.849 billion, and Q2 net profit was -115 million. Based on this calculation, Q3 net profit turned a profit from a quarter-on-quarter loss.